SCHEMBL3491065

SCHEMBL3491065

O=C(CCCCCCCCc1ccc2ccc3cccc4ccc1c2c34)ON1C(=O)CCC1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.54
MEN1 O00255 1/20 0.54
FAAH O00519 1/20 0.38
ITPR1 Q14643 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MTNR1A P48039 1/20 0.35
GBA1 P04062 2/20 0.35
UGCG Q16739 2/20 0.35
GBA2 Q9HCG7 2/20 0.35
POLB P06746 2/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
CYP2D6 P10635 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HTT P42858 1/20 0.34
PSMB8 P28062 1/20 0.33
PSMB5 P28074 1/20 0.33
NAAA Q02083 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19328246 0.99 KMT2A (0.55) KMT2AMEN1FAAHITPR1KDM4E
SCHEMBL388103 0.96 KMT2A (0.58) KMT2AMEN1FAAHITPR1KDM4E
SCHEMBL29367875 0.96 KMT2A (0.58) KMT2AMEN1FAAHITPR1KDM4E
SCHEMBL23824231 0.93 KMT2A (0.54) KMT2AMEN1FAAHITPR1KDM4E
SCHEMBL1804142 0.91 KMT2A (0.52) KMT2AMEN1FAAHITPR1KDM4E
SCHEMBL2957090 0.90 KMT2A (0.41) KMT2AMEN1FAAHKDM4EALDH1A1
Butyric Acid SCHEMBL28642804 0.89 KMT2A (0.59) KMT2AMEN1FAAHITPR1KDM4E
SCHEMBL2958220 0.86 KMT2A (0.44) KMT2AMEN1FAAHKDM4EALDH1A1
SCHEMBL21972140 0.86 MEN1 (0.44) KMT2AMEN1FAAHALDH1A1CYP1A2
Aminopyrene SCHEMBL23831545 0.85 KMT2A (0.38) KMT2AMEN1FAAHKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304520-B2 Labeled fusion protein THE UNIVERSITY OF TOKYO (JP) 2012-11-06 US disclosed
US-20100105882-A1 MOLECULAR MODULE THE UNIVERSITY OF TOKYO (JP) 2010-04-29 US disclosed
EP-2098538-A1 MOLECULAR MODULE The University of Tokyo (JP) 2009-09-09 EP disclosed
US-20050118605-A9 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation ISIS PHARMACEUTICALS, INC. 2005-06-02 US disclosed
US-20050037370-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation BAKER BRENDA F (US) 2005-02-17 US disclosed
US-20050032069-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation ISIS PHARMACEUTICALS, INC. 2005-02-10 US disclosed
WO-2004044245-A1 OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE AND GUANINE AND THEIR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2004-05-27 WO disclosed
EP-0644890-B1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INST OF BR EX PH (AU) 2001-12-05 EP disclosed
EP-0383803-B1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INST OF (AU) 2000-05-03 EP disclosed
EP-0972779-A2 Oligonucleotide-polyamide conjugates HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 2000-01-19 EP disclosed
US-5846728-A Oligonucleotide-polyamide conjugates HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1998-12-08 US disclosed
US-5677440-A Oligonucleotide-polyamide conjugates HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1997-10-14 US disclosed
US-5552540-A NONRADIOACTIVE LABELS HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1996-09-03 US disclosed
EP-0644890-A4 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES. FLOREY HOWARD INST (AU) 1996-03-27 EP disclosed
EP-0644890-A1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1995-03-29 EP disclosed
EP-0366685-B1 NUCLEOSIDE DERIVATIVES FLOREY HOWARD INST (AU) 1994-10-19 EP disclosed
WO-1993024511-A1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1993-12-09 WO disclosed
EP-0366685-A4 NUCLEOSIDE DERIVATIVES 1991-03-20 EP disclosed
EP-0366685-A1 NUCLEOSIDE DERIVATIVES. FLOREY HOWARD INST (AU) 1990-05-09 EP disclosed
WO-1988010264-A1 NUCLEOSIDE DERIVATIVES HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY (AU) 1988-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037370-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 KMT2A 3013/4885MEN1 3504/4885FAAH 4818/4885
US-20050118605-A9 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 KMT2A 3013/4885MEN1 3504/4885FAAH 4818/4885
US-20050032069-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 KMT2A 3013/4885MEN1 3504/4885FAAH 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.